Author:
Mao Yu,Zhao Yu,Zhang Xiaodong,Zheng Jiemin,Lu Guocai,Yuan Bojun
Subject
Toxicology,General Medicine
Reference54 articles.
1. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure;Abraham;J. Card. Failure,1998
2. In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications
3. Abraham, W.T., 2005b. Nesiritide does not increase 30-day or 6-month mortality risk [abstract 3169]. Circulation 112 (17 Suppl. II), II-676.
4. Abraham, W.T., 2005c. Effect of baseline covariates on mortality risk in the vasodilation in the management of acute congestive heart failure (VMAC) trial [abstract 2790]. Circulation. 112 (17 Suppl. II), 589.
5. Arnold L.M, Carroll, N.V., Oinonen, M., et al., 2004. Mortality and length of hospital stay in patients receiving dobutamine, milrinone, or nesiritide for acute decompensated heart failure [abstract 317]. J. Card. Fail. 10(Suppl. 4), S103.